

What is claimed is:

1. A method of treating a mammal having edema comprising administering to said mammal an effective amount of hVEGF antagonist.

5 2. The method of claim 1 wherein said edema comprises cerebral edema.

3. The method of claim 1 wherein said mammal is a human further having a neoplastic disease.

10 4. The method of claim 3 wherein said neoplastic disease comprises a brain tumor.

15 5. The method of claim 4 wherein said hVEGF antagonist is administered to said mammal serially or in combination with chemotherapy or radiation therapy.

6. The method of claim 1 wherein said mammal is a human further having or having undergone a stroke.

20 7. The method of claim 1 wherein said hVEGF antagonist comprises an anti-hVEGF antibody.

8. The method of claim 7 wherein said anti-hVEGF antibody comprises a chimeric antibody.

25 9. The method of claim 7 wherein said anti-hVEGF antibody comprises a humanized antibody.

30 10. The method of claim 7 wherein said antibody comprises a monoclonal antibody.

11. The method of claim 1 wherein said hVEGF antagonist comprises a hVEGF receptor fusion protein.

12. The method of claim 11 wherein said hVEGF receptor fusion protein comprises an extracellular domain sequence of a hVEGF receptor fused to an immunoglobulin.

5 13. The method of claim 12 wherein said hVEGF receptor fusion protein comprises a flt-IgG fusion protein.

14. A method of treating a mammal having or having undergone a stroke, comprising administering to said mammal an effective amount of hVEGF
10 antagonist.

15. The method of claim 14 wherein said hVEGF antagonist comprises an anti-hVEGF antibody.

15 16. The method of claim 15 wherein said anti-hVEGF antibody comprises a chimeric antibody.

17. The method of claim 15 wherein said anti-hVEGF antibody comprises a humanized antibody.
20

18. The method of claim 15 wherein said antibody comprises a monoclonal antibody.

19. The method of claim 14 wherein said hVEGF antagonist comprises a hVEGF
25 receptor fusion protein.

20. The method of claim 19 wherein said hVEGF receptor fusion protein comprises an extracellular domain sequence of a hVEGF receptor fused to an immunoglobulin.
30

21. The method of claim 20 wherein said hVEGF receptor fusion protein comprises a flt-IgG fusion protein.

35

Sub
B12

22. A method of treating a mammal having cerebral edema comprising administering to said mammal an effective amount of hVEGF antagonist.

5 23. The method of claim 22 wherein said hVEGF antagonist comprises an anti-hVEGF antibody.

24. The method of claim 23 wherein said anti-hVEGF antibody comprises a chimeric antibody.

10 25. The method of claim 23 wherein said anti-hVEGF antibody comprises a humanized antibody.

26. The method of claim 23 wherein said antibody comprises a monoclonal antibody.

15

27. The method of claim 22 wherein said hVEGF antagonist comprises a hVEGF receptor fusion protein.

20

28. The method of claim 27 wherein said hVEGF receptor fusion protein comprises an extracellular domain sequence of a hVEGF receptor fused to an immunoglobulin.

25

29. The method of claim 28 wherein said hVEGF receptor fusion protein comprises a flt-IgG fusion protein.